<DOC>
	<DOCNO>NCT01725451</DOCNO>
	<brief_summary>This study evaluate effect deodorant antiperspirant use presence underarm hair absorption testosterone . Each participant study receive 6 single dos 30 milligram ( mg ) testosterone apply solution underarm . There minimum one day washout period dose . This study last approximately 24 day include screening . Screening require within 30 day prior start study .</brief_summary>
	<brief_title>A Study Effect Deodorant Axillary Hair Testosterone Absorption Healthy Participants</brief_title>
	<detailed_description />
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>Are overtly healthy male , determine medical history physical examination Agree use reliable method birth control ( example , condom vasectomy ) study 1 month follow last dose testosterone Have total testosterone level &lt; 400 nanogram per deciliter ( ng/dL ) base local laboratory result Have hemoglobin â‰¥12 gram per deciliter ( g/dL ) screening , participant take break study , retest Weigh least 60 kilogram ( kg ) Have venous access sufficient allow blood sampling Are reliable willing make available duration study willing follow study procedure Have give write informed consent approve Eli Lilly Company ( Lilly ) ethical review board ( ERB ) govern site Use topical testosterone replacement therapy within 2 week prior randomization last dosing period , except use testosterone solution direct study procedure Use parenteral testosterone replacement ( testosterone enanthanate , testosterone cypionate ) within 30 day prior screen . Use longacting intramuscular testosterone undecanoate 6 month prior screen , use testosterone pellet 12 month prior screen Have body mass index &gt; 35 kilogram per square meter ( kg/m^2 ) Have significant history allergy and/or sensitivity drug product excipients , include history sensitivity testosterone Currently use medication , herbal , and/or nutritional supplement interfere testosterone Have dermatologic condition underarm area might interfere testosterone absorption ( example , eczema ) exacerbate topical testosterone replacement therapy Have history presence of/significant history current cardiovascular , respiratory , hepatic , renal , endocrine , hematological , neurological disorder constitute risk take study medication could interfere interpretation data Have lymphoma , leukemia , malignancy within past 5 year except basal cell squamous epithelial carcinoma skin resect evidence metastatic disease 3 year Have abnormal prostatespecific antigen ( PSA ) test result Have know allergy testosterone solution , related compound component formulation , history significant atopy Have abnormality 12lead electrocardiogram ( ECG ) , opinion investigator , increase risk associate participate study Have abnormal blood pressure determine investigator Regularly use know drug abuse and/or show positive finding urinary drug screen Show evidence hepatitis B and/or positive hepatitis B surface antigen Show evidence hepatitis C and/or positive hepatitis C antibody Show evidence human immunodeficiency ( HIV ) infection and/or positive human HIV antibody Are participant previously complete withdrawn study study investigate testosterone Are currently enrol , discontinue within last 30 day , clinical trial involve investigational product nonapproved use drug device ( investigational product use study ) , concurrently enrol type medical research judge scientifically medically compatible study In opinion investigator sponsor , unsuitable inclusion study Have shave axilla within 3 month screen</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>